Price T Rowe Associates Inc Krystal Biotech, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 600,145 shares of KRYS stock, worth $106 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
600,145
Previous 658,618
8.88%
Holding current value
$106 Million
Previous $117 Million
5.95%
% of portfolio
0.01%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding KRYS
# of Institutions
266Shares Held
25MCall Options Held
270KPut Options Held
172K-
Black Rock Inc. New York, NY3.95MShares$699 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.87MShares$508 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.43MShares$431 Million6.1% of portfolio
-
State Street Corp Boston, MA1.33MShares$236 Million0.01% of portfolio
-
Redmile Group, LLC San Francisco, CA1.02MShares$181 Million12.22% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.55B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...